Log in

Charles River Laboratories Intl. Stock Price, News & Analysis (NYSE:CRL)

$135.28
+0.52 (+0.39 %)
(As of 10/18/2019 01:15 AM ET)
Today's Range
$134.66
Now: $135.28
$136.26
50-Day Range
$125.63
MA: $132.86
$139.35
52-Week Range
$103.00
Now: $135.28
$149.07
Volume171,373 shs
Average Volume360,787 shs
Market Capitalization$6.60 billion
P/E Ratio22.43
Dividend YieldN/A
Beta1.09
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP15986410
Phone781-222-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.27 billion
Cash Flow$9.57 per share
Book Value$27.37 per share

Profitability

Net Income$226.37 million

Miscellaneous

Employees14,700
Market Cap$6.60 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive CRL News and Ratings via Email

Sign-up to receive the latest news and ratings for CRL and its competitors with MarketBeat's FREE daily newsletter.


Charles River Laboratories Intl. (NYSE:CRL) Frequently Asked Questions

What is Charles River Laboratories Intl.'s stock symbol?

Charles River Laboratories Intl. trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

How were Charles River Laboratories Intl.'s earnings last quarter?

Charles River Laboratories Intl. Inc (NYSE:CRL) released its earnings results on Wednesday, July, 31st. The medical research company reported $1.63 EPS for the quarter, topping analysts' consensus estimates of $1.55 by $0.08. The medical research company had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. Charles River Laboratories Intl.'s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.62 EPS. View Charles River Laboratories Intl.'s Earnings History.

When is Charles River Laboratories Intl.'s next earnings date?

Charles River Laboratories Intl. is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Charles River Laboratories Intl..

What guidance has Charles River Laboratories Intl. issued on next quarter's earnings?

Charles River Laboratories Intl. updated its FY19 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $6.45-6.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.46. The company issued revenue guidance of +16-18% yr/yr to ~$2.63-2.67 billion, compared to the consensus revenue estimate of $2.65 billion.

What price target have analysts set for CRL?

14 analysts have issued 1 year price objectives for Charles River Laboratories Intl.'s stock. Their predictions range from $136.00 to $162.00. On average, they expect Charles River Laboratories Intl.'s stock price to reach $150.36 in the next year. This suggests a possible upside of 11.1% from the stock's current price. View Analyst Price Targets for Charles River Laboratories Intl..

What is the consensus analysts' recommendation for Charles River Laboratories Intl.?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories Intl. in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Charles River Laboratories Intl..

Has Charles River Laboratories Intl. been receiving favorable news coverage?

News stories about CRL stock have trended somewhat negative on Friday, according to InfoTrie. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Charles River Laboratories Intl. earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Charles River Laboratories Intl..

Are investors shorting Charles River Laboratories Intl.?

Charles River Laboratories Intl. saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 1,070,000 shares, a decline of 7.8% from the August 30th total of 1,160,000 shares. Based on an average daily trading volume, of 322,300 shares, the short-interest ratio is currently 3.3 days. Approximately 2.2% of the company's stock are short sold. View Charles River Laboratories Intl.'s Current Options Chain.

Who are some of Charles River Laboratories Intl.'s key competitors?

What other stocks do shareholders of Charles River Laboratories Intl. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories Intl. investors own include Celgene (CELG), Boeing (BA), Intuitive Surgical (ISRG), Intel (INTC), Abbott Laboratories (ABT), Alibaba Group (BABA), Emerson Electric (EMR), Johnson & Johnson (jnj), Merck & Co., Inc. (MRK) and Procter & Gamble (PG).

Who are Charles River Laboratories Intl.'s key executives?

Charles River Laboratories Intl.'s management team includes the folowing people:
  • Mr. James C. Foster, Chairman, CEO & Pres (Age 68)
  • Mr. David Ross Smith, Corp. Exec. VP & CFO (Age 53)
  • Mr. David P. Johst, Corp. Exec. VP, HR, Gen. Counsel & Chief Admin. Officer (Age 57)
  • Mr. William D. Barbo, Chief Commercial Officer & Corp. Exec. VP (Age 58)
  • Mr. Michael Gunnar Knell, Corp. Sr. VP & Chief Accounting Officer (Age 42)

Who are Charles River Laboratories Intl.'s major shareholders?

Charles River Laboratories Intl.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (0.29%), Envestnet Asset Management Inc. (0.14%), Three Peaks Capital Management LLC (0.06%), Pacer Advisors Inc. (0.04%), Nisa Investment Advisors LLC (0.03%) and Crossmark Global Holdings Inc. (0.03%). Company insiders that own Charles River Laboratories Intl. stock include Birgit Girshick, Bradley Nixon Scharfe, C Richard Reese, David P Johst, David Ross Smith, Davide Molho, Deborah Turner Kochevar, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Kevin Ma, Online Communications Bdirect, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Institutional Ownership Trends for Charles River Laboratories Intl..

Which institutional investors are selling Charles River Laboratories Intl. stock?

CRL stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Pacer Advisors Inc., Nisa Investment Advisors LLC, Crossmark Global Holdings Inc., National Investment Services Inc. WI and NEXT Financial Group Inc. Company insiders that have sold Charles River Laboratories Intl. company stock in the last year include David P Johst, David Ross Smith, George M Milne Jr, George Massaro, James C Foster, Joseph W Laplume, Robert J Bertolini, Stephen D Chubb and William D Barbo. View Insider Buying and Selling for Charles River Laboratories Intl..

Which institutional investors are buying Charles River Laboratories Intl. stock?

CRL stock was bought by a variety of institutional investors in the last quarter, including Three Peaks Capital Management LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Nelson Van Denburg & Campbell Wealth Management Group LLC, We Are One Seven LLC and First Hawaiian Bank. View Insider Buying and Selling for Charles River Laboratories Intl..

How do I buy shares of Charles River Laboratories Intl.?

Shares of CRL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Charles River Laboratories Intl.'s stock price today?

One share of CRL stock can currently be purchased for approximately $135.28.

How big of a company is Charles River Laboratories Intl.?

Charles River Laboratories Intl. has a market capitalization of $6.60 billion and generates $2.27 billion in revenue each year. The medical research company earns $226.37 million in net income (profit) each year or $6.03 on an earnings per share basis. Charles River Laboratories Intl. employs 14,700 workers across the globe.View Additional Information About Charles River Laboratories Intl..

What is Charles River Laboratories Intl.'s official website?

The official website for Charles River Laboratories Intl. is http://www.criver.com/.

How can I contact Charles River Laboratories Intl.?

Charles River Laboratories Intl.'s mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company can be reached via phone at 781-222-6000 or via email at [email protected]


MarketBeat Community Rating for Charles River Laboratories Intl. (NYSE CRL)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  357 (Vote Outperform)
Underperform Votes:  440 (Vote Underperform)
Total Votes:  797
MarketBeat's community ratings are surveys of what our community members think about Charles River Laboratories Intl. and other stocks. Vote "Outperform" if you believe CRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel